OptiNose, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 11th, 2017 • OptiNose, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 11th, 2017 Company Industry Jurisdiction
EMPLOYMENT AGREEMENTEmployment Agreement • October 11th, 2017 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 11th, 2017 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on October [ ], 2017, by and between OPTINOSE US, INC., a Delaware corporation (the “Company”), and Michael F. Marino (“Executive”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 11th, 2017 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 11th, 2017 Company Industry JurisdictionThis Indemnification Agreement (this “Agreement”) is made as of [ ], 2017 by and between OptiNose, Inc., a Delaware corporation (the “Corporation”), in its own name and on behalf of its direct and indirect subsidiaries, and [ ], an individual (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Corporation and Indemnitee covering the subject matter of this Agreement.
FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT OF OPTINOSE, INC.Shareholder Agreements • October 11th, 2017 • OptiNose, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 11th, 2017 Company IndustryTHIS FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT (this “Amendment”), dated as of October 2, 2017, by and among OptiNose, Inc., a Delaware corporation (the “Company”), the Investors, the Existing Shareholders and the Management Shareholders party thereto.
FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT OF OPTINOSE, INC.Registration Rights Agreement • October 11th, 2017 • OptiNose, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 11th, 2017 Company IndustryTHIS FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Amendment”), dated as of October 2, 2017, by and among OptiNose, Inc., a Delaware corporation (the “Company”), and the holders of Series D Shares, Series C-2 Shares, Series C-1 Shares, Series C Shares and Series B Shares of the Company identified on the signature pages thereto (collectively, the “Investors”).